Cargando…

Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis

Overdiagnosis and overtreatment of clinically insignificant tumors remains a major problem in prostate cancer (PC) due to suboptimal diagnostic and prognostic tools. Thus, novel biomarkers are urgently needed. In this study, we investigated the biomarker potential of Trefoil factor 3 (TFF3) promoter...

Descripción completa

Detalles Bibliográficos
Autores principales: Nørgaard, Maibritt, Haldrup, Christa, Storebjerg, Tine Maj, Vestergaard, Else Marie, Wild, Peter J., Høyer, Søren, Borre, Michael, Ørntoft, Torben Falck, Sørensen, Karina Dalsgaard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618665/
https://www.ncbi.nlm.nih.gov/pubmed/28930171
http://dx.doi.org/10.3390/ijms18092017
_version_ 1783267240341143552
author Nørgaard, Maibritt
Haldrup, Christa
Storebjerg, Tine Maj
Vestergaard, Else Marie
Wild, Peter J.
Høyer, Søren
Borre, Michael
Ørntoft, Torben Falck
Sørensen, Karina Dalsgaard
author_facet Nørgaard, Maibritt
Haldrup, Christa
Storebjerg, Tine Maj
Vestergaard, Else Marie
Wild, Peter J.
Høyer, Søren
Borre, Michael
Ørntoft, Torben Falck
Sørensen, Karina Dalsgaard
author_sort Nørgaard, Maibritt
collection PubMed
description Overdiagnosis and overtreatment of clinically insignificant tumors remains a major problem in prostate cancer (PC) due to suboptimal diagnostic and prognostic tools. Thus, novel biomarkers are urgently needed. In this study, we investigated the biomarker potential of Trefoil factor 3 (TFF3) promoter methylation and RNA expression levels for PC. Initially, by quantitative methylation specific PCR (qMSP) analysis of a large radical prostatectomy (RP) cohort (n = 292), we found that the TFF3 promoter was significantly hypomethylated in PC compared to non-malignant (NM) prostate tissue samples (p < 0.001) with an AUC (area under the curve) of 0.908 by receiver operating characteristics (ROC) curve analysis. Moreover, significant TFF3 promoter hypomethylation (p ≤ 0.010) as well as overexpression (p < 0.001) was found in PC samples from another large independent patient sample set (498 PC vs. 67 NM) analyzed by Illumina 450K DNA methylation arrays and/or RNA sequencing. TFF3 promoter methylation and transcriptional expression levels were inversely correlated, suggesting that epigenetic mechanisms contribute to the regulation of gene activity. Furthermore, low TFF3 expression was significantly associated with high ERG, ETS transcription factor (ERG) expression (p < 0.001), as well as with high Gleason score (p < 0.001), advanced pathological T-stage (p < 0.001), and prostate-specific antigen (PSA) recurrence after RP (p = 0.013; univariate Cox regression analysis). There were no significant associations between TFF3 promoter methylation levels, ERG status, or PSA recurrence in these RP cohorts. In conclusion, our results demonstrated diagnostic biomarker potential of TFF3 promoter hypomethylation for PC as well as prognostic biomarker potential of TFF3 RNA expression. To the best of our knowledge, this is the most comprehensive study of TFF3 promoter methylation and transcriptional expression in PC to date.
format Online
Article
Text
id pubmed-5618665
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-56186652017-09-30 Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis Nørgaard, Maibritt Haldrup, Christa Storebjerg, Tine Maj Vestergaard, Else Marie Wild, Peter J. Høyer, Søren Borre, Michael Ørntoft, Torben Falck Sørensen, Karina Dalsgaard Int J Mol Sci Article Overdiagnosis and overtreatment of clinically insignificant tumors remains a major problem in prostate cancer (PC) due to suboptimal diagnostic and prognostic tools. Thus, novel biomarkers are urgently needed. In this study, we investigated the biomarker potential of Trefoil factor 3 (TFF3) promoter methylation and RNA expression levels for PC. Initially, by quantitative methylation specific PCR (qMSP) analysis of a large radical prostatectomy (RP) cohort (n = 292), we found that the TFF3 promoter was significantly hypomethylated in PC compared to non-malignant (NM) prostate tissue samples (p < 0.001) with an AUC (area under the curve) of 0.908 by receiver operating characteristics (ROC) curve analysis. Moreover, significant TFF3 promoter hypomethylation (p ≤ 0.010) as well as overexpression (p < 0.001) was found in PC samples from another large independent patient sample set (498 PC vs. 67 NM) analyzed by Illumina 450K DNA methylation arrays and/or RNA sequencing. TFF3 promoter methylation and transcriptional expression levels were inversely correlated, suggesting that epigenetic mechanisms contribute to the regulation of gene activity. Furthermore, low TFF3 expression was significantly associated with high ERG, ETS transcription factor (ERG) expression (p < 0.001), as well as with high Gleason score (p < 0.001), advanced pathological T-stage (p < 0.001), and prostate-specific antigen (PSA) recurrence after RP (p = 0.013; univariate Cox regression analysis). There were no significant associations between TFF3 promoter methylation levels, ERG status, or PSA recurrence in these RP cohorts. In conclusion, our results demonstrated diagnostic biomarker potential of TFF3 promoter hypomethylation for PC as well as prognostic biomarker potential of TFF3 RNA expression. To the best of our knowledge, this is the most comprehensive study of TFF3 promoter methylation and transcriptional expression in PC to date. MDPI 2017-09-20 /pmc/articles/PMC5618665/ /pubmed/28930171 http://dx.doi.org/10.3390/ijms18092017 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nørgaard, Maibritt
Haldrup, Christa
Storebjerg, Tine Maj
Vestergaard, Else Marie
Wild, Peter J.
Høyer, Søren
Borre, Michael
Ørntoft, Torben Falck
Sørensen, Karina Dalsgaard
Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis
title Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis
title_full Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis
title_fullStr Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis
title_full_unstemmed Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis
title_short Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis
title_sort comprehensive evaluation of tff3 promoter hypomethylation and molecular biomarker potential for prostate cancer diagnosis and prognosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618665/
https://www.ncbi.nlm.nih.gov/pubmed/28930171
http://dx.doi.org/10.3390/ijms18092017
work_keys_str_mv AT nørgaardmaibritt comprehensiveevaluationoftff3promoterhypomethylationandmolecularbiomarkerpotentialforprostatecancerdiagnosisandprognosis
AT haldrupchrista comprehensiveevaluationoftff3promoterhypomethylationandmolecularbiomarkerpotentialforprostatecancerdiagnosisandprognosis
AT storebjergtinemaj comprehensiveevaluationoftff3promoterhypomethylationandmolecularbiomarkerpotentialforprostatecancerdiagnosisandprognosis
AT vestergaardelsemarie comprehensiveevaluationoftff3promoterhypomethylationandmolecularbiomarkerpotentialforprostatecancerdiagnosisandprognosis
AT wildpeterj comprehensiveevaluationoftff3promoterhypomethylationandmolecularbiomarkerpotentialforprostatecancerdiagnosisandprognosis
AT høyersøren comprehensiveevaluationoftff3promoterhypomethylationandmolecularbiomarkerpotentialforprostatecancerdiagnosisandprognosis
AT borremichael comprehensiveevaluationoftff3promoterhypomethylationandmolecularbiomarkerpotentialforprostatecancerdiagnosisandprognosis
AT ørntofttorbenfalck comprehensiveevaluationoftff3promoterhypomethylationandmolecularbiomarkerpotentialforprostatecancerdiagnosisandprognosis
AT sørensenkarinadalsgaard comprehensiveevaluationoftff3promoterhypomethylationandmolecularbiomarkerpotentialforprostatecancerdiagnosisandprognosis